What Is the Orforglipron Weight Loss Pill?

In recent years, weight loss medications have taken a huge leap forward. Patients now have more choices than ever for their weight loss journey. Many new options are being announced and entering clinical testing.

However, the current crop of weekly injection won’t suit everyone. Many people in the UK are asking whether a tablet could do a similar job. Enter orforglipron, a new oral weight loss tablet from Eli Lilly (makers of Mounjaro).

This article explains what orforglipron is, how it works, what we know about results and side effects. We also cover what to expect for the UK release date and potential cost.

What Is Orforglipron?

Orforglipron is an oral medicine (a tablet) being developed for weight management and type 2 diabetes.

It works similarly to glucagon-like peptide 1 (GLP-1) medicines like Mounjaro and Wegovy, helping to reduce appetite and support blood sugar levels. However, orforglipron is a small molecule rather than a peptide.

Peptide medicines are easily broken down in the stomach. In order to avoid being broken down, most GLP-1s are injections. However, small-molecule drugs aren’t broken down as easily in the stomach, so you can take them orally.

The main point for UK readers is that orforglipron is still being tested. It is not yet approved for weight loss in the UK. That means you should not be able to buy it legally from a UK pharmacy yet. Any website claiming to sell it now should be treated with extreme caution.

How Does It Work?

Your body naturally makes a hormone called glucagon-like peptide-1 (GLP-1) after you eat. GLP-1 helps you feel fuller, slows how quickly food leaves your stomach and supports steadier blood sugar levels.

Orforglrion mimics the hormone GLP-1. This can reduce hunger and make it easier to eat less without feeling constantly hungry.

Orforglipron is designed as a once-daily tablet. Early research suggests it lasts long enough in the body for daily use. Orforglipron may not need the same strict “take it on an empty stomach” routine used for some other GLP-1 tablets.

Orforglipron aims to give the appetite control of GLP-1 injections in a tablet form. This could appeal to people who do not want injections or have issues using them.

How Effective Is Orforglipron for Weight Loss?

Because orforglipron is not yet widely available, the best evidence comes from clinical trials. They showed significant weight loss from a daily pill dosing scheme.

• Phase 2 trial (36 weeks, adults with obesity or overweight, without diabetes):
  People taking once-daily orforglipron lost more weight than people taking a placebo. At week 26, average weight loss across dose groups ranged from about 8.6% to 12.6%. By week 36, it ranged from about 9.4% to 14.7% (placebo was around 2% to 2.3%).
• Phase 3 trial (72 weeks, adults with obesity, without diabetes):
  In one published phase 3 trial, average weight loss at week 72 was about 7.5% (6 mg), 8.4% (12 mg), and 11.2% (36 mg), compared with about 2.1% with placebo.

These are average figures. Some people will lose more, and some less. Trials also include lifestyle support (diet and activity advice), which are key components to getting the most out of obesity management medications.

How Does This Compare to Mounjaro?

Mounjaro (tirzepatide) works differently than orforglipron. Mounjaro works on two hormone pathways (GIP and GLP-1), while orforglipron targets GLP-1 only.

In the major 72-week obesity trial for tirzepatide, average weight loss was around 15% (5 mg), 19.5% (10 mg) and 20.9% (15 mg) compared with 3.1% with placebo.

That is not a perfect comparison. Different trials, different people and different designs can lead to slightly different results. It shows the range of results from current injection options compared to what has been published for this medication.

Orforglipron, compared to Mounjaro, may give some patients less average weight loss. However, the ease of taking a daily tablet may outweigh the reduced effectiveness compared to Mounjaro.

What Are the Side Effects of Orforglipron?

So far, the side effects reported look similar to the GLP-1 medicine “family” in general. The most common issues are gastrointestinal, such as nausea, diarrhoea, vomiting, constipation and stomach discomfort. These effects are often mild to moderate and are more likely during dose increases or when you start the medication.

In the phase 2 trial, gastrointestinal side effects were common and led some people to stop treatment.

Like other GLP-1 medicines, there are also less common but more serious risks that can occur. These include severe allergic reactions, severe ongoing stomach pain or signs of dehydration.

If a medicine like this is prescribed in the future, your doctor should check if it is safe for you. They should also explain what the warning signs mean.

Orforglipron is not yet licensed in the UK for weight loss. The final UK safety advice will only be clear once a UK product leaflet is published. This includes the official list of warnings and side effects.

How Often Do You Take Orforglipron?

In studies, orforglipron has been taken once daily by mouth.

One reason it has gained attention is that early research says it is studied without strict food and water limits. This may make daily use easier than some other oral GLP-1 options.

Still, suggested doses of orforglipron can change between trials and the final approved label. If it is approved, follow the UK patient leaflet and prescriber advice rather than social media tips.

When Will Orforglipron Be Available in the UK?

As of 21 January 2026, Eli Lilly’s orforglipron for weight loss is not licensed in the UK.

For a medicine to be available on prescription in the UK, it needs regulatory approval (by the MHRA). For NHS use, there is usually an extra step: NICE reviews the evidence and decides who should be offered it on the NHS.

You may also see headlines about US timelines. For example, reports have talked about when the US might approve and how to plan supplies. However, this is not the same as when the UK will have them available. UK timing will depend on the UK regulatory and commissioning process.

If you see a site claiming it can ship “orforglipron” to the UK now, treat it as a red flag. Medicines sold outside regulated routes can be fake, wrong strength or unsafe.

How Much Will Orforglipron Cost?

Right now, there is no official UK price for orforglipron as a weight loss treatment, because it is not yet licensed and marketed here.

What we can say is:

• NHS cost (if it is ever offered) would depend on negotiations and NICE recommendations. 
• Private costs in the UK (if it launches privately first) can vary widely between providers. The cost may include clinical monitoring and support as well as the medicine itself.
• US pricing headlines do not translate directly to the UK. For example, Reuters reported a planned US cash price point, but UK pricing and access rules are different.

If you are budgeting, the honest answer is that UK costs are still unclear. This will remain until a UK launch is confirmed and prices are published.

Key Takeaways

• Orforglipron is a daily weight loss tablet in development: It is a once-a-day pill being studied for weight loss and type 2 diabetes, but it is not yet approved for weight management in the UK.
• It works like other GLP-1 medicines, but in tablet form: It aims to reduce hunger and help you feel fuller, which can make it easier to eat less and lose weight over time.
• Trials show meaningful weight loss, but results vary: Studies have shown average weight loss that increases with higher doses, but some people lose more than average and some lose less.
• Side effects are mostly stomach-related: The most common side effects in studies are nausea, diarrhoea, vomiting, constipation and stomach discomfort, especially when the dose is increased.
• UK timing and cost are still unclear: You cannot legally buy orforglipron for weight loss in the UK yet, and there is no confirmed UK price until it is approved and launched.

References

Eli Lilly and Company, 2025. Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial [Online]. Available from: https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically.

Eli Lilly and Company, 2025. What to know about orforglipron: oral GLP-1 [Online]. Available from: https://www.lilly.com/news/stories/what-to-know-about-orforglipron.

Gateshead Health NHS Foundation Trust, 2024. Oral GLP-1 analogues (Semaglutide) [Online]. Available from: https://www.gatesheadhealth.nhs.uk/resources/oral-glp-1-analogues-semaglutide/.

Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M.C. & Stefanski, A., 2022. Tirzepatide once weekly for the treatment of obesity, The New England Journal of Medicine, 387(3), pp.205–216 [Online]. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038.

National Center for Biotechnology Information (NCBI), 2020. Obesity: Epidemiology, Pathophysiology, and Prevention [online]. In: StatPearls. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551568/.

National Institute for Health and Care Excellence (NICE), 2026. Orforglipron for managing overweight and obesity (Reference: GID-TA11650) [Online]. Available from:https://www.nice.org.uk/guidance/indevelopment/gid-ta11650.

Pratt, E., Amblee, A., Brown, K., et al., 2023. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes, Obesity and Metabolism, 25(9) [online]. Available from: https://pubmed.ncbi.nlm.nih.gov/37344954/.

Reuters, 2026. Lilly says it’s confident on weight-loss pill supply ahead of U.S. approval [Online]. Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-says-its-confident-weight-loss-pill-supply-ahead-us-approval-2026-01-12/.

UK Government, 2024. GLP-1 medicines for weight loss and diabetes: what you need to know [Online]. Available from:https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know.

Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K.J., Haupt, A., Robins, D. & Pratt, E. et al., 2023. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity, The New England Journal of Medicine, 389(10), pp.877-888 [online]. Available from: https://pubmed.ncbi.nlm.nih.gov/37351564/.

Authorship